Table 1 COVID-19 Studies with cancer and cardiovascular disease epidemiology (through April 22, 2020)
Author Country Clinical setting Number of institutions Date of publication Number of patients in study with COVID-19 Canceran (%) Predominant cancer n (%) HTN n (%) CVDbn (%) Mortality in cancer patients n (%)
Wu C, et al. China Hospitalized 1 March 13,2020 201 1(0.5) Not specified 39 (19.4) 8 (4.0) Not reported
Guo T, et al. China Hospitalized 1 March 27, 2020 187 13(7) Not specified 61 (32.6) 29 (15.5) Not reported
Zhou F, et al. China Hospitalized 2 March 9, 2020 191 2(1) Not specified 58 (30.4) 15 (8) 0
Shi S, et al. China Hospitalized 1 March 25, 2020 416 9(2.2) Not specified 127 (30.5) 61 (14.7) Not reported
Liang W, et al. China Hospitalized 575 February 14, 2020 1590 18(1.1) Lung - 5 (28) Not reported Not reported Not reported
Onder G, et al. Italy Not specified Not specified March 23, 2020 355 72 (20.3) Not specified Not specified 117 (33) 100 (Study only reviewed cases that died)
Grasselli G, et al.c Italy Intensive care units 72 April 6, 2020 1043 81(8) Not specified 509 (49) 223 (21) Not reported
McMichael T, et al. USA Long-term care facility 1 March 27, 2020 167 15(9) Not specified 74 (44.3) 68 (40.7) Not reported
Goyal P, et al. USA Hospitalized 2 April 17, 2020 393 23(5.9) Not specified 197 (50.1) 82 (21) Not reported
Richardson, et al. USA Hospitalized 17 April 22, 2020 5700 320(6) Not specified 3026 (56.6)c 966 (18)d Not reported
aCancer was defined in studies as either cancer, tumor, malignant neoplasm, or carcinoma. There was variability in whether cancer was active or in remission
bThere were various definitions utilized for cardiovascular disease across all studies not limited to cardiomyopathy, coronary artery disease, and ischemic heart disease
c,dHistory regarding these comorbidities may not have been available for all patients enrolled in the study; hence, percentage does not correlate the with total number of patients in the study
HTN hypertension, CVD cardiovascular disease